Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - H.C. Wainwright reiterated its Buy rating and $40.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), currently valued at $236.77 million, following the company’s presentation of Phase 1/2 data for CRB-701 at ESMO 2025. The stock has shown remarkable momentum, surging 220.4% over the past six months, with analyst targets ranging from $28 to $55.
The data showed promising objective response rates (ORR) across multiple tumor types in heavily pretreated patients, with 47.6% in head and neck squamous cell carcinoma (HNSCC), 37.5% in cervical cancer, and 55.6% in metastatic urothelial carcinoma at the 3.6 mg/kg dose level.
CRB-701 demonstrated efficacy across various Nectin-4+ expression levels, HPV status, and PD(L)-1 responses in solid tumors, highlighting its broad clinical utility, which has been recognized with FDA Fast Track Designations in both second-line HNSCC and recurrent/refractory cervical cancer.
Among 167 enrolled patients, CRB-701 maintained a strong safety profile with only 18% Grade 3 treatment-related adverse events, no dose-limiting toxicities, no Grade 4 or 5 treatment-emergent adverse events, and a low discontinuation rate of 6%, with peripheral neuropathy occurring in just 8.4% of patients (all Grade 1 or 2).
The reduced dosing frequency of CRB-701 was noted as a potential advantage for physician preference, with key opinion leaders viewing it as an attractive option for combination second-line therapies in HNSCC despite a competitive market landscape. InvestingPro subscribers have access to 14 additional investment tips for CRBP, including detailed analysis of the company’s financial health and market positioning.
In other recent news, Corbus Pharmaceuticals has been in the spotlight due to several key developments. The company announced that updated clinical data from its Phase 1/2 study of CRB-701, a Nectin-4-targeting antibody-drug conjugate, will be presented at the European Society for Medical Oncology Congress in October. This presentation will include results from trials involving patients with urothelial and non-urothelial solid tumors. Corbus also received FDA Fast Track Designation for CRB-701, aimed at treating recurrent or metastatic head and neck squamous cell carcinoma. Analyst firm Mizuho reiterated an Outperform rating and a $32.00 price target on Corbus, expressing interest in the potential of CRB-701 for head and neck cancer. Oppenheimer, while maintaining an Outperform rating, adjusted its price target for Corbus from $60.00 to $53.00. The firm highlighted the significance of results from approximately 100 additional patients treated with CRB-701. These developments have generated considerable interest among investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.